Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Epidural Abscess Treatment Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for treating epidural abscesses has experienced robust expansion recently, projecting a rise from $43.78 billion in 2025 to $46.6 billion in 2026, reflecting a compound annual growth rate of 6.4%. This expansion during the past period is linked to factors such as the occurrence of spinal infections, the dangers associated with delayed diagnoses, the accessibility of antibiotics, the availability of neurosurgical services in hospitals, and the overall prevalence of infectious diseases.

The market for epidural abscess treatments is poised for significant expansion over the coming years, projected to reach $62.27 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.5%. This anticipated surge in the forecast period is underpinned by several key factors, including enhanced access to advanced imaging technologies, the implementation of early intervention strategies, advancements in antimicrobial therapies, the expansion of hospital infrastructure, and increased awareness among healthcare professionals. Furthermore, prevailing trends expected to shape this market include a greater emphasis on early diagnostic imaging, a growing reliance on broad-spectrum antibiotics, an increase in surgical intervention rates, the development of specialized hospital-based infection care, and a dedicated focus on mitigating neurological complications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12904&type=smp

Epidural Abscess Treatment Market Industry Drivers: What Is Driving Revenue Growth?

The escalating incidence of neurological conditions is anticipated to stimulate the expansion of the epidural abscess treatment market. Neurological disorders encompass a range of ailments affecting the nervous system, including the brain, spinal cord, and peripheral nerves, with examples such as acute spinal cord injury, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). Epidural abscess treatment is a critical intervention for these conditions, typically involving immediate surgical drainage of the abscess alongside antibiotic therapy to alleviate pressure on the spinal cord and nerves, thereby preventing potential damage. Illustrating this prevalence, the Alzheimer’s Association reported in April 2025 that an estimated 7.2 million individuals aged 65 and over were living with Alzheimer’s disease in the US in 2025, with associated annual care costs, exclusive of unpaid care, projected to reach $384 billion. Consequently, the growing number of individuals affected by neurological disorders is a key factor driving the epidural abscess treatment market.

An increase in the practice of injecting drugs intravenously is poised to drive the expansion of the epidural abscess treatment market. Intravenous drug administration involves introducing substances directly into the bloodstream via a needle and syringe. This method can lead to the development of epidural abscesses when contaminated equipment or substances introduce bacteria or other pathogens into the circulatory system, thereby elevating the occurrence of this condition and escalating the demand for specialized medical interventions, treatments, and preventative measures. As an illustration, data from the Australian Institute of Health and Welfare, released in June 2025, indicated that methamphetamine was the most frequently reported drug injected nationally in 2023, cited by 53% of users, with this figure persisting at 59% in 2024 and 56% in 2023 among those who identified it as their most commonly injected substance. Therefore, the rising trend of intravenous drug use is a significant contributor to the growth of the epidural abscess treatment market.

The upward trend in healthcare spending is expected to foster the growth of the epidural abscess treatment market. Health expenditures encompass the totality of costs associated with healthcare services, family planning initiatives, nutritional programs, and health-focused emergency aid. An augmented level of healthcare spending is instrumental in the context of epidural abscess treatment, as it facilitates the advancement of more effective therapeutic strategies and sophisticated medical technologies for managing this condition. For example, the UK’s Office for National Statistics reported in May 2023 that total healthcare expenditure in the United Kingdom amounted to approximately $362.08 billion (£292 billion) in 2023, marking a nominal increase of 5.6%; however, healthcare spending as a proportion of the Gross Domestic Product (GDP) saw a slight reduction, declining to 10.9% in 2023 from 11.1% in 2022. Consequently, the increase in healthcare expenditures serves as a catalyst for the expansion of the epidural abscess treatment market.

Epidural Abscess Treatment Market Segmentation: How Is The Market Structured Across Key Categories?

The epidural abscess treatment market covered in this report is segmented –

1) By Type: Intracranial, Intraspinal

2) By Treatment: Antifungal, Antibiotics, Surgery

3) By End-User: Hospital, Pharmacy, Specialty Clinics, Other End-Users

Subsegments:

1) By Intracranial: Brain Abscess, Subdural Abscess, Epidural Abscess in the Cranium

2) By Intraspinal: Cervical Epidural Abscess, Thoracic Epidural Abscess, Lumbar Epidural Abscess, Sacral Epidural Abscess

Epidural Abscess Treatment Market Competitive Landscape And Leading Companies

Major companies operating in the epidural abscess treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma, Daiichi Sankyo Company Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Kyowa Hakko Kirin Co. Ltd., Hikma Pharmaceuticals plc, Intas Pharmaceuticals Limited, Alembic Limited, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals

Access The Complete Epidural Abscess Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/epidural-abscess-treatment-global-market-report

Epidural Abscess Treatment Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the epidural abscess treatment market in 2025. The regions covered in the epidural abscess treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model